Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance (NASDAQ: IOVA) reported positive early pilot data for lifileucel in advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), showing a 50% confirmed objective response rate (ORR) among the first six evaluable patients.
Patients were heavily pretreated (mean >2 prior lines) with mean baseline tumor burden of 117 mm. Safety was described as favorable and consistent with prior lifileucel studies. Iovance plans a single-arm registrational trial in second-line UPS and DDLPS in Q2 2026 and will engage the FDA for an accelerated approval path.
Iovance (NASDAQ: IOVA) reported fourth-quarter 2025 product revenue of approximately $87 million (about 30% quarter-over-quarter growth) and full-year 2025 revenue of ~$264 million, achieving guidance of $250M–$300M. Gross margin improved to ~50% and cash of ~$303 million is expected to fund operations into Q3 2027.
Key commercial and clinical updates include continued Amtagvi uptake, global regulatory progress, FDA Fast Track designation for lifileucel in previously treated NSCLC, and pipeline trial advances with registrational plans targeting potential lifileucel launch in H2 2027.
Iovance (NASDAQ: IOVA) approved inducement stock options covering 3,600 shares for two new non-executive employees on February 19, 2026. Each option has an exercise price of $2.85 and vests over three years with time-based quarterly installments.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Iovance Biotherapeutics (NASDAQ: IOVA) will report fourth quarter and full year 2025 financial results and provide corporate updates via a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET.
According to the company, the live and archived webcast will be available on the Investors section of its website and the archived webcast will remain accessible for one year.
Iovance (NASDAQ: IOVA) reported real-world, retrospective data showing Amtagvi (lifileucel) achieved a 44% confirmed objective response rate and 73% disease control rate in 41 evaluable advanced melanoma patients treated per U.S. prescribing information.
Response was higher when used earlier: 52% ORR after two or fewer prior therapies versus 33% ORR after three or more lines. The company cites prior trial results of ~31% ORR and a median duration of response of 36+ months with 20% five-year overall survival; a Phase 3 frontline trial is ongoing.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock option grants on January 15, 2026 covering an aggregate of 97,710 shares to 17 new non-executive employees under the Amended and Restated 2021 Inducement Plan.
Each option has an exercise price of $2.22 (the closing price on the Date of Grant) and vests over three years: one-third on the first anniversary of each employee’s start date and the remainder in eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) announced on Dec 18, 2025 inducement stock option grants covering an aggregate of 43,150 shares to four new non-executive employees under its Amended and Restated 2021 Inducement Plan.
Each option has an exercise price of $2.46 (the closing price on the Date of Grant) and vests over three years: one-third at the first anniversary of each employee’s start date, then the remainder in eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on November 20, 2025 covering an aggregate of 164,900 shares granted to 11 new non-executive employees under its Amended and Restated 2021 Inducement Plan.
Each option has an exercise price of $2.18 (the closing price on the Date of Grant) and vests over three years: one-third on the first anniversary of each employee’s start date and the remainder in eight quarterly installments over the next two years, subject to continued employment.
The plan was originally adopted on September 22, 2021 and amended on January 12, 2022; March 13, 2023; February 26, 2024; and November 22, 2024, and grants were approved by the company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Iovance (NASDAQ: IOVA) reported Q3 2025 product revenue of ~$68 million (up 13% QoQ) with gross margin of 43% and cost of sales of ~$39 million. Cash, investments, and restricted cash totaled ~$307 million as of Sept 30, 2025, projected to fund operations into Q2 2027. The company reaffirmed full‑year 2025 revenue guidance of $250–$300 million. Commercial updates: >80 U.S. authorized treatment centers, ~95% of patients within a two‑hour drive, and manufacturing turnaround of 32 days. Regulatory and pipeline: Health Canada approval for Amtagvi (Aug 2025) and positive lifileucel data in nonsquamous NSCLC (ORR 26%; mDOR not reached at >25 months); enrollment and registrational trials planned through 2026–2027.
Iovance (NASDAQ: IOVA) reported interim registrational Phase 2 IOV-LUN-202 data for lifileucel in previously treated advanced nonsquamous NSCLC: an objective response rate (ORR) of 25.6% (10/39 patients), including 2 complete responses, and a disease control rate of 71.8%. The median duration of response was not reached after a median follow-up of 25.4 months. The FDA gave positive regulatory feedback on trial design and potency assays. Iovance expects to progress toward a supplemental BLA in 2026 with a potential commercial launch in H2 2027. Safety trends improved after a reduced lymphodepletion regimen, with shorter post-IL-2 hospital stays.